Table 2.
Results of the base-case analysis.
| Scenario | Regimen | Total cost (USD) | LYs | QALYs | CER (USD/LY) | CER (USD/QALY) | ICER (USD/LY) | ICER (USD/QALY) |
|---|---|---|---|---|---|---|---|---|
| ITT patients | Nab-paclitaxel | 8,524 | 1.87 | 1.297 | 4,558 | 6,572 | ||
| Atezolizumab + nab-paclitaxel | 83,700 | 2.606 | 1.724 | 32,118 | 48,550 | 102,141 | 176,056 | |
| PD-L1(+) patients | Nab-paclitaxel | 8,007 | 1.836 | 1.259 | 4,361 | 6,360 | ||
| Atezolizumab + nab-paclitaxel | 99,688 | 3.101 | 2.035 | 32,147 | 48,987 | 72,475 | 118,146 | |
| PD-L1(–) patients | Nab-paclitaxel | 9,211 | 1.907 | 1.34 | 4,830 | 6,874 | ||
| Atezolizumab + nab-paclitaxel | 76,411 | 2.316 | 1.548 | 32,993 | 49,361 | 164,303 | 323,077 |
ITT, intention-to-treat; PD-L1, programmed death ligand-1; LY, life-year; QALY, quality-adjusted life-year; CER, average cost-effectiveness ratio; ICER, incremental cost-effectiveness ratio; USD, United States dollar.